Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
Panbela Therapeutics, Inc. (PBLA)
Company Research
Source: GlobeNewswire
MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced an Issue Notification for the US continuation patent US 11,925,613 B2 and Canadian patent CA 3003149 titled “EFLORNITHINE AND SULINDAC, A FIXED DOSE COMBINATION FORMULATION”. These patents claim a novel composition of a fixed dose combination of eflornithine and sulindac, which is called Flynpovi. The product was developed in collaboration with Sanofi, an innovative global healthcare company. Flynpovi is Panbela’s lead investigational product for the treatment of patients with Familial Adenomatous Polyposis (FAP). The patents are valid until 2036, have issued in the US, Australia, Mexico, Taiwan, and Chile. The application is under review in additional countries. Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela Therapeutic
Show less
Read more
Impact Snapshot
Event Time:
PBLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PBLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PBLA alerts
High impacting Panbela Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PBLA
News
- Panbela Therapeutics, Inc. (NASDAQ: PBLA) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- Panbela Provides Business Update and Reports Q1 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Panbela Provides Business Update and Reports Q1 2024 Financial ResultsGlobeNewswire
- Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024GlobeNewswire
- Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease WeekGlobeNewswire
PBLA
Earnings
- 5/15/24 - Miss
PBLA
Analyst Actions
- 5/16/24 - HC Wainwright
PBLA
Sec Filings
- 5/16/24 - Form 424B3
- 5/16/24 - Form 424B3
- 5/16/24 - Form 424B3
- PBLA's page on the SEC website